BRIEF-Artelo Biosciences Receives Favorable Uk Mhra Guidance For A Phase 1 Trial Of Art12.11, The Company’S Proprietary CbdTmp Cocrystal Being Developed For The Treatment Of Anxiety And Depression

Reuters
Aug 01
BRIEF-<a href="https://laohu8.com/S/ARTL">Artelo Biosciences</a> Receives Favorable Uk Mhra Guidance For A Phase 1 Trial Of Art12.11, The Company’S Proprietary CbdTmp Cocrystal Being Developed For The Treatment Of Anxiety And Depression

Artelo Biosciences Inc ARTL.O:

  • ARTELO BIOSCIENCES RECEIVES FAVORABLE UK MHRA GUIDANCE FOR A PHASE 1 TRIAL OF ART12.11, THE COMPANY’S PROPRIETARY CBD:TMP COCRYSTAL BEING DEVELOPED FOR THE TREATMENT OF ANXIETY AND DEPRESSION

  • ARTELO BIOSCIENCES INC - UK REGULATORY ASSURANCE EXPECTED TO REDUCE EXPENSES FOR ART12.11

Source text: ID:nGNX37jwf8

Further company coverage: ARTL.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10